Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 3
1998 4
1999 8
2000 28
2001 154
2002 343
2003 592
2004 641
2005 692
2006 755
2007 881
2008 810
2009 857
2010 854
2011 884
2012 842
2013 792
2014 752
2015 620
2016 584
2017 538
2018 489
2019 487
2020 488
2021 447
2022 446
2023 395
2024 132

Text availability

Article attribute

Article type

Publication date

Search Results

12,920 results

Results by year

Filters applied: . Clear all
Page 1
The argument for using imatinib in CML.
Claudiani S, Apperley JF. Claudiani S, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504305 Free PMC article. Review.
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for patients with this disease is one of the major success stories of modern cancer medicine. .. …
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid le …
Kinase drug discovery 20 years after imatinib: progress and future directions.
Cohen P, Cross D, Jänne PA. Cohen P, et al. Nat Rev Drug Discov. 2021 Jul;20(7):551-569. doi: 10.1038/s41573-021-00195-4. Epub 2021 May 17. Nat Rev Drug Discov. 2021. PMID: 34002056 Free PMC article. Review.
Here, we review the remarkable progress made over the past 20 years in improving the potency and specificity of small-molecule inhibitors of protein and lipid kinases, resulting in the approval of more than 70 new drugs since imatinib was approved in 2001. These compounds …
Here, we review the remarkable progress made over the past 20 years in improving the potency and specificity of small-molecule inhibitors of …
Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, Ray-Coquard I, Tabone S, Méeus P, Ranchère D, Sunyach MP, Decouvelaere AV, Alberti L, Blay JY. Cassier PA, et al. Expert Opin Pharmacother. 2008 May;9(7):1211-22. doi: 10.1517/14656566.9.7.1211. Expert Opin Pharmacother. 2008. PMID: 18422477 Review.
GISTs have since been recognized as separate pathological entities among sarcomas, and have become a model for targeted treatment of solid tumours. Imatinib mesilate, which was approved in 2002 for the treatment of patients with advanced GIST, has dramatically chang …
GISTs have since been recognized as separate pathological entities among sarcomas, and have become a model for targeted treatment of solid t …
Is there something other than imatinib mesilate in therapeutic options for GIST?
Giuliani F, Colucci G. Giuliani F, et al. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S35-43. doi: 10.1517/14728222.2012.657627. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443297 Review.
INTRODUCTION: In the last decade, the introduction of imatinib mesilate into the clinical practice has resulted in a dramatic improvement in the treatment of gastrointestinal stromal tumor (GIST). ...AREAS COVERED: Summarized and investigated in this paper are the r …
INTRODUCTION: In the last decade, the introduction of imatinib mesilate into the clinical practice has resulted in a dramatic …
Imatinib-induced generalized vitiligo.
Jain A. Jain A. Br J Haematol. 2022 Jun;197(5):511. doi: 10.1111/bjh.18096. Epub 2022 Mar 14. Br J Haematol. 2022. PMID: 35285938 No abstract available.
Imatinib-induced eruptive nevi.
Hamie L, Sawaya RT, Abbas O. Hamie L, et al. Clin Exp Pharmacol Physiol. 2021 Sep;48(9):1298-1299. doi: 10.1111/1440-1681.13491. Epub 2021 Mar 25. Clin Exp Pharmacol Physiol. 2021. PMID: 33768564
Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. ...Despite the well-known association of eruptive melanocytic nevi with the use of other tyrosine kinase inhibitors, this phenomenon has not been linked to …
Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. ...Despite the …
Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination.
Sun X, Zhang Q, Lin X, Shu P, Gao X, Shen K. Sun X, et al. Cell Death Dis. 2023 Dec 18;14(12):839. doi: 10.1038/s41419-023-06300-2. Cell Death Dis. 2023. PMID: 38110356 Free PMC article.
Imatinib (IM) has significantly improved the prognosis of gastrointestinal stromal tumor (GIST) patients, but some patients still have primary resistance to IM, and approximately half of patients develop acquired drug resistance within 2 years of treatment, necessitating e …
Imatinib (IM) has significantly improved the prognosis of gastrointestinal stromal tumor (GIST) patients, but some patients still hav …
N(6)-methyladenosine-modified USP13 induces pro-survival autophagy and imatinib resistance via regulating the stabilization of autophagy-related protein 5 in gastrointestinal stromal tumors.
Gao Z, Li C, Sun H, Bian Y, Cui Z, Wang N, Wang Z, Yang Y, Liu Z, He Z, Li B, Li F, Li Z, Wang L, Zhang D, Yang L, Xu Z, Li X, Xu H. Gao Z, et al. Cell Death Differ. 2023 Feb;30(2):544-559. doi: 10.1038/s41418-022-01107-8. Epub 2022 Dec 17. Cell Death Differ. 2023. PMID: 36528756 Free PMC article.
Secondary resistance to imatinib (IM) represents a major challenge for therapy of gastrointestinal stromal tumors (GISTs). ...
Secondary resistance to imatinib (IM) represents a major challenge for therapy of gastrointestinal stromal tumors (GISTs). ...
Future options for imatinib mesilate-resistant tumors.
Sankhala KK, Papadopoulos KP. Sankhala KK, et al. Expert Opin Investig Drugs. 2007 Oct;16(10):1549-60. doi: 10.1517/13543784.16.10.1549. Expert Opin Investig Drugs. 2007. PMID: 17922620 Review.
The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate (imatinib mesylate), a KIT and platelet-derived growth factor (PDGFR) tyrosine kinase inhibitor. ...This review discusses the …
The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate …
12,920 results
You have reached the last available page of results. Please see the User Guide for more information.